Get Involved
A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)
Study Purpose
The primary purpose of this study is to compare pembrolizumab/vibostolimab to pembrolizumab with respect to recurrence-free survival (RFS). The primary hypothesis is that pembrolizumab/vibostolimab is superior to pembrolizumab with respect to RFS as assessed by the investigator in participants with high-risk resected Stage IIB, IIC, III and IV melanoma.
Recruitment Criteria
|
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
|
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
| Eligible Ages | 12 Years and Over |
| Gender | All |
Inclusion Criteria:
- - Has surgically resected and histologically or pathologically confirmed diagnosis of Stage IIB and IIC (pathological or clinical), III, or IV cutaneous melanoma per the American Joint Committee on Cancer (AJCC) eighth edition guidelines.
- - Has not received any prior systemic therapy for melanoma beyond surgical resection.
- - Has had no more than 12 weeks between final surgical resection and randomization.
- - Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART) - Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization.
- - Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening.
Exclusion Criteria:
- - Has ocular, mucosal, or conjunctival melanoma.
- - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication.
- - Has not adequately recovered from major surgical procedure or has ongoing surgical complications.
- - Has received prior radiotherapy within 2 weeks of start of study intervention or has had a history of radiation pneumonitis.
- - Received a live or live attenuated vaccine within 30 days before the first dose of study intervention.
- - Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration.
- - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
- - Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.
- - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- - Has an active autoimmune disease that has required systemic treatment in past 2 years.
- - Has an active infection requiring systemic therapy.
Trial Details
|
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT05665595 |
|
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
|
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
Merck Sharp & Dohme LLC |
|
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Medical Director |
| Principal Investigator Affiliation | Merck Sharp & Dohme LLC |
|
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
| Overall Status | Active, not recruiting |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, India, Ireland, Israel, Italy, Japan, Korea, Republic of, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States |
|
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Melanoma |
| Study Website: | View Trial Website |
With Amendment 4, participants will discontinue treatment with pembrolizumab/vibostolimab. The protocol-specified futility analysis of the primary outcome measure was completed with a data cut-off of 06-Mar-2024 (Primary Completion Date) and served as the final analysis of the primary outcome measure. Per protocol, 192 participants enrolled after the primary completion date and will be analyzed in the End of Trial analysis.
Arms
Experimental: Pembrolizumab/Vibostolimab
Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Active Comparator: Pembrolizumab
Participants receive 200 mg pembrolizumab via IV infusion on Day 1 of each cycle (cycle length = 3 weeks) for up to 17 cycles (up to ~1 year).
Interventions
Biological: - Pembrolizumab/Vibostolimab
Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 17 administrations
Biological: - Pembrolizumab
Pembrolizumab 25 mg/mL administered as IV infusion for up to 17 administrations
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Moores Cancer Center ( Site 0116)
La Jolla, California, 92093-0698
Status
Address
The Angeles Clinic and Research Institute - West Los Angeles Office ( Site 0123)
Los Angeles, California, 90025
Status
Address
UCLA Hematology/Oncology - Westwood (Building 100) ( Site 0131)
Los Angeles, California, 90095
Status
Address
California Pacific Medical Center - Pacific Campus ( Site 0111)
San Francisco, California, 94115
Status
Address
UCSF Medical Center at Mission Bay ( Site 0130)
San Francisco, California, 94158
Status
Address
The Melanoma & Skin Cancer Institute ( Site 0120)
Englewood, Colorado, 80113
Status
Address
Georgetown University Medical Center ( Site 0144)
Washington, District of Columbia, 20007
Status
Address
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0110)
Miami, Florida, 33136
Status
Address
Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center ( Site 0124)
Tampa, Florida, 33612
Status
Address
Northwestern Memorial Hospital ( Site 0109)
Chicago, Illinois, 60611
Status
Address
Advocate Medical Group-Oncology ( Site 0102)
Park Ridge, Illinois, 60068
Status
Address
University of Iowa-Holden Comprehensive Cancer Center ( Site 0107)
Iowa City, Iowa, 52242
Status
Address
Henry Ford Hospital ( Site 0133)
Detroit, Michigan, 48202
Status
Address
Comprehensive Cancer Centers of Nevada ( Site 0142)
Las Vegas, Nevada, 89169
Status
Address
R.J. Zuckerberg Cancer Center-Medical Oncology ( Site 0132)
Lake Success, New York, 11042
Status
Address
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0146)
Mineola, New York, 11501
Status
Address
Laura and Isaac Perlmutter Cancer Center-Hematology and Oncology ( Site 0113)
New York, New York, 10016
Status
Address
Icahn School of Medicine at Mount Sinai ( Site 0118)
New York, New York, 10029
Status
Address
Weill Cornell Medical College ( Site 0115)
New York, New York, 10065
Status
Address
Levine Cancer Institute ( Site 0138)
Charlotte, North Carolina, 28204
Status
Address
Sanford Fargo Medical Center ( Site 0127)
Fargo, North Dakota, 58102
Status
Address
Children's Hospital of Pittsburgh ( Site 0141)
Pittsburgh, Pennsylvania, 15224
Status
Address
UPMC Hillman Cancer Center ( Site 0135)
Pittsburgh, Pennsylvania, 15232
Status
Address
Sanford Cancer Center ( Site 0125)
Sioux Falls, South Dakota, 57104
Status
Address
The West Clinic, PLLC dba West Cancer Center ( Site 0119)
Germantown, Tennessee, 38138
Status
Address
St. Jude Children's Research Hospital ( Site 0106)
Memphis, Tennessee, 38105
Status
Address
Vanderbilt University Medical Center ( Site 0139)
Nashville, Tennessee, 37232
Status
Address
University of Texas MD Anderson Cancer Center ( Site 0145)
Houston, Texas, 77030
Status
Address
Inova Schar Cancer Institute ( Site 0103)
Fairfax, Virginia, 22031
Status
Address
University of Wisconsin Hospital and Clinics ( Site 0108)
Madison, Wisconsin, 53792
International Sites
Status
Address
Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0204)
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1027AAP
Status
Address
Instituto Alexander Fleming-Alexander Fleming ( Site 0209)
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1426ANZ
Status
Address
Centro de Educación Médica e Investigaciones Clínicas (CEMIC) ( Site 0200)
Buenos Aires, Caba, C1431FWO
Status
Address
Instituto de Oncología de Rosario ( Site 0206)
Rosario, Santa Fe, S2000KZE
Status
Address
Sanatorio Finochietto ( Site 0212)
Buenos Aires, , C1187AAN
Status
Address
Clinica Adventista Belgrano-Oncology ( Site 0211)
Caba, , C1430EGF
Status
Address
Blacktown Hospital-Blacktown Cancer and Haematology Centre - Medical Oncology ( Site 1464)
Blacktown, New South Wales, 2148
Status
Address
Calvary Mater Newcastle-Medical Oncology ( Site 1462)
Waratah, New South Wales, 2298
Status
Address
Melanoma Institute Australia-Clinical Trials Unit ( Site 1450)
Wollstonecraft, New South Wales, 2065
Status
Address
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Si
Brisbane, Queensland, 4029
Status
Address
Cairns Hospital-Clinical Research Unit ( Site 1458)
Cairns, Queensland, 4870
Status
Address
Gallipoli Medical Research Ltd-GMRF CTU ( Site 1451)
Greenslopes, Queensland, 4120
Status
Address
Tasman Oncology Research ( Site 1456)
Southport, Queensland, 4215
Status
Address
Royal Adelaide Hospital-RAH Cancer Centre ( Site 1457)
Adelaide, South Australia, 5000
Status
Address
Icon Cancer Centre Hobart ( Site 1465)
Hobart, Tasmania, 7000
Status
Address
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 1455)
Melbourne, Victoria, 3000
Status
Address
One Clinical Research ( Site 1460)
Nedlands, Western Australia, 6009
Status
Address
Universitätsklinikum St. Pölten-Department of Dermatology ( Site 0606)
St. Polten, Niederosterreich, 3100
Status
Address
Ordensklinikum Linz GmbH Elisabethinen-Dermatologie ( Site 0602)
Linz, Oberosterreich, 4020
Status
Address
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0601)
Graz, Steiermark, 8036
Status
Address
Medizinische Universitaet Innsbruck-Univ Klinik für Dermatologie, Venerologie und Allergologie ( Sit
Innsbruck, Tirol, 6020
Status
Address
Medizinische Universität Wien-Department of Dermatology ( Site 0600)
Vienna, Wien, 1090
Status
Address
Uniklinikum Salzburg-Department of Dermatology and Allergology ( Site 0604)
Salzburg, , 5020
Status
Address
GZA Ziekenhuizen campus Sint-Augustinus ( Site 0655)
Wilrijk, Antwerpen, 2610
Status
Address
Cliniques universitaires Saint-Luc ( Site 0652)
Brussels, Bruxelles-Capitale, Region De, 1200
Status
Address
Jessa Ziekenhuis ( Site 0656)
Hasselt, Limburg, 3500
Status
Address
Université Catholique de Louvain-Namur - Centre Hospitalier -Oncology ( Site 0653)
Yvoir, Namur, 5530
Status
Address
VITAZ-Medical Oncology ( Site 0654)
Sint-Niklaas, Oost-Vlaanderen, B-9100
Status
Address
UZ Leuven-General Medical Oncology ( Site 0650)
Leuven, Vlaams-Brabant, 3000
Status
Address
Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 0256)
Belo Horizonte, Minas Gerais, 30130090
Status
Address
Hospital de Cancer de Londrina-Clinical Research Unit ( Site 0252)
Londrina, Parana, 86015-520
Status
Address
Associação Hospitalar Beneficente São Vicente de Paulo-Instituto do Câncer ( Site 0259)
Passo Fundo, Rio Grande Do Sul, 99010-080
Status
Address
ANIMI - Unidade de Tratamento Oncologico ( Site 0255)
Lages, Santa Catarina, 88501001
Status
Address
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia ( Site 0262)
Santo André, Sao Paulo, 09060-870
Status
Address
A. C. Camargo Cancer Center ( Site 0258)
Sao Paulo, , 01509-010
Status
Address
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0004)
Ottawa, Ontario, K1H 8L6
Status
Address
Sunnybrook Research Institute ( Site 0003)
Toronto, Ontario, M4N 3M5
Status
Address
Princess Margaret Cancer Centre ( Site 0006)
Toronto, Ontario, M5G 2M9
Status
Address
Oncocentro Valdivia ( Site 0307)
Valdivia, Los Rios, 5112129
Status
Address
FALP-UIDO ( Site 0303)
Santiago, Region M. De Santiago, 7500921
Status
Address
Oncovida ( Site 0304)
Santiago, Region M. De Santiago, 7510032
Status
Address
Clínica UC San Carlos de Apoquindo ( Site 0305)
Santiago, Region M. De Santiago, 7620002
Status
Address
Bradfordhill-Clinical Area ( Site 0302)
Santiago, Region M. De Santiago, 8420383
Status
Address
ONCOCENTRO APYS-ACEREY ( Site 0300)
Viña del Mar, Valparaiso, 2520598
Status
Address
Bradford Hill Norte ( Site 0308)
Antofagasta, , 1240000
Status
Address
Beijing Ji Shui Tan Hospital ( Site 1657)
Beijing, Beijing, 100035
Status
Address
Beijing Cancer hospital-Renal carcinoma and melanoma ( Site 1650)
Beijing, Beijing, 100142
Status
Address
Chongqing University Cancer Hospital ( Site 1651)
Chongqing, Chongqing, 400030
Status
Address
Fujian Provincial Cancer Hospital ( Site 1659)
Fuzhou, Fujian, 350014
Status
Address
Sun Yat-sen University Cancer Center-melanoma ( Site 1655)
Guangzhou, Guangdong, 510060
Status
Address
Guangxi Medical University Affiliated Tumor Hospital ( Site 1668)
Nanning, Guangxi, 530021
Status
Address
Fourth Hospital of Hebei Medical University ( Site 1669)
Shijiazhuang, Hebei, 050035
Status
Address
The Third Hospital of Zhengzhou-Oncology ( Site 1653)
Zhengzhou Shi, Henan, 450001
Status
Address
Wuhan Union Hospital Cancer Center-Cancer Center ( Site 1664)
Wuhan, Hubei, 430022
Status
Address
The Second Xiangya Hospital of Central South University-Oncology ( Site 1673)
Changsha, Hunan, 410011
Status
Address
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Oncology (
NanJing, Jiangsu, 210000
Status
Address
Jiangsu Province Hospital-Oncology Department ( Site 1663)
Nanjing, Jiangsu, 210029
Status
Address
The First Affiliated Hospital of Nanchang University ( Site 1652)
Nanchang, Jiangxi, 330006
Status
Address
The First Hospital of Jilin University-Oncology ( Site 1665)
Changchun, Jilin, 130021
Status
Address
Fudan University Shanghai Cancer Center ( Site 1658)
Shanghai, Shanghai, 200032
Status
Address
Shanxi Bethune Hospital ( Site 1660)
Taiyuan, Shanxi, 030032
Status
Address
West China Hospital, Sichuan University-Head and Neck Oncology ( Site 1667)
Cheng Du, Sichuan, 610041
Status
Address
Tianjin Medical University Cancer Institute & Hospital-Biotherapy ( Site 1671)
Tianjin, Tianjin,
Status
Address
Xinjiang Medical University Cancer Hospital - Urumqi-Bone and Soft Tissue Department ( Site 1674)
Urumqi, Xinjiang, 830000
Status
Address
Yunnan Province Cancer Hospital-Biotherapy Center ( Site 1666)
Kunming, Yunnan, 650106
Status
Address
Zhejiang Cancer Hospital-Oncology ( Site 1661)
Hangzhou, Zhejiang, 310022
Status
Address
Instituto de Cancerología ( Site 0356)
Medellin, Antioquia, 050025
Status
Address
Fundación Colombiana de Cancerología Clínica Vida ( Site 0355)
Medellin, Antioquia, 050030
Status
Address
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0358)
Bogota, Distrito Capital De Bogota, 111321
Status
Address
Mediservis del Tolima IPS S.A.S ( Site 0357)
Ibague, Tolima, 730006
Status
Address
Fundación Valle del Lili ( Site 0352)
Cali, Valle Del Cauca, 760032
Status
Address
Centre Hospitalier de Valence-Service de Dermatologie ( Site 0702)
Valence, Drome, 26953
Status
Address
Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu-Onco-Dermatology ( Site 0707)
Nantes, Loire-Atlantique, 44093
Status
Address
Institut de Cancérologie de l'Ouest-Oncologie Médicale ( Site 0706)
Saint Herblain, Loire-Atlantique, 44805
Status
Address
Hopital Claude Huriez - CHU de Lille-Clinique de Dermatologie ( Site 0700)
Lille, Nord-Pas-de-Calais, 59037
Status
Address
Assistance Publique Hôpitaux de Marseille - Hôpital de la Ti-Service de Dermatologie et Cancérologi
Marseille, Provence-Alpes-Cote-d Azur, 13005
Status
Address
Centre Hospitalier de Pau ( Site 0708)
Pau, Pyrenees-Atlantiques, 64000
Status
Address
centre hospitalier lyon sud-Service de dermatologie ( Site 0714)
Pierre-Bénite, Rhone, 69310
Status
Address
Gustave Roussy-Dermatologie ( Site 0713)
Villejuif, Val-de-Marne, 94800
Status
Address
Hopitaux Universitaires Paris Centre-Hopital Cochin ( Site 0711)
Paris, , 75014
Status
Address
Universitaetsklinikum Heidelberg ( Site 0765)
Heidelberg, Baden-Wurttemberg, 69120
Status
Address
Universitätsmedizin Mannheim ( Site 0751)
Mannheim, Baden-Wurttemberg, 68167
Status
Address
Universitaetsklinikum Erlangen-Hautklinik ( Site 0750)
Erlangen, Bayern, 91054
Status
Address
Klinik und Poliklinik für Dermatologie und Allergologie-Dermato-oncology ( Site 0757)
München, Bayern, 80337
Status
Address
Elbe Kliniken Stade-Buxtehude, Klinikum Buxtehude-Dermatologisches Zentrum ( Site 0754)
Buxtehude, Niedersachsen, 21614
Status
Address
Medizinische Hochschule Hannover ( Site 0758)
Hannover, Niedersachsen, 30625
Status
Address
Universitaetsklinikum Essen-Klinik für Dermatologie, Venerologie und Allergologie ( Site 0761)
Essen, Nordrhein-Westfalen, 45147
Status
Address
Johannes Wesling Klinikum Minden-Skin Cancer Center Minden ( Site 0759)
Minden, Nordrhein-Westfalen, 32429
Status
Address
Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Dermatologie ( Site 0766)
Dresden, Sachsen, 01307
Status
Address
Universitätsklinikum Leipzig ( Site 0762)
Leipzig, Sachsen, 04103
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel-Hautklinik ( Site 0767)
Kiel, Schleswig-Holstein, 24105
Status
Address
Charité Universitaetsmedizin Berlin - Campus Mitte-Hauttumorcentrum Charité (HTCC) ( Site 0756)
Berlin, , 10117
Status
Address
Universitaetsklinikum Hamburg-Eppendorf ( Site 0752)
Hamburg, , 20246
Status
Address
All India Institute of Medical Sciences-Medical oncology ( Site 1552)
New Delhi, Delhi, 110029
Status
Address
Artemis hospital ( Site 1551)
Gurugram, Haryana, 122001
Status
Address
Tata Memorial Hospital-Medical Oncology ( Site 1550)
Mumbai, Maharashtra, 400012
Status
Address
St. James's Hospital-Cancer clinical trials office ( Site 0900)
Dublin, , D08 E9P6
Status
Address
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 0902)
Dublin, , Dublin 9
Status
Address
Emek Medical Center-oncology ( Site 0952)
Afula, , 1834111
Status
Address
Soroka Medical Center ( Site 0953)
Be'er Sheva, , 8410101
Status
Address
Rambam Health Care Campus-Oncology Division ( Site 0955)
Haifa, , 3109601
Status
Address
Hadassah Medical Center ( Site 0951)
Jerusalem, , 9112001
Status
Address
Rabin Medical Center-Oncology ( Site 0954)
Petah Tikva, , 4941492
Status
Address
Sheba Medical Center-ONCOLOGY ( Site 0950)
Ramat Gan, , 5265601
Status
Address
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori ( Site 1004)
Meldola, Emilia-Romagna, 47014
Status
Address
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1000)
Milan, Lombardia, 20133
Status
Address
Instituto Tumori Giovanni Paolo II ( Site 1003)
Bari, Puglia, 70124
Status
Address
A.O.U. Policlinico Paolo Giaccone-Depatment of Discipline Chirurgiche, Oncologiche e Stomatologiche
Palermo, Sicilia, 90129
Status
Address
Azienda Ospedaliero Universitaria Senese ( Site 1005)
Siena, Toscana, 53100
Status
Address
AO Santa Maria della Misericordia ( Site 1006)
Perugia, Umbria, 06129
Status
Address
Istituto Europeo di Oncologia IRCCS ( Site 1008)
Milano, , 20141
Status
Address
Azienda Ospedaliero Universitaria ( Site 1002)
Modena, , 41125
Status
Address
Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1001)
Napoli, , 80131
Status
Address
Nagoya University Hospital ( Site 1753)
Nagoya-Shi, Aichi, 466-8560
Status
Address
Sapporo Medical University Hospital ( Site 1755)
Sapporo, Hokkaido, 060-8543
Status
Address
Niigata Cancer Center Hospital ( Site 1751)
Niigata-shi, Niigata, 951-8566
Status
Address
Shizuoka Cancer Center ( Site 1752)
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777
Status
Address
National Cancer Center Hospital ( Site 1750)
Chuo-ku, Tokyo, 104-0045
Status
Address
Osaka International Cancer Institute ( Site 1754)
Osaka, , 541-8567
Status
Address
Seoul National University Hospital-Oncology ( Site 1600)
Seoul, , 03080
Status
Address
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1601)
Seoul, , 03722
Status
Address
Samsung Medical Center-Division of Hematology/Oncology ( Site 1602)
Seoul, , 06351
Status
Address
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1501)
Tauranga, Bay Of Plenty, 3112
Status
Address
New Zealand Clinical Research (Christchurch) ( Site 1509)
Christchurch, Canterbury, 8011
Status
Address
P3 Research - Palmerston North ( Site 1510)
Palmerston North, Manawatu-Wanganui, 4414
Status
Address
Dunedin Hospital ( Site 1511)
Dunedin, Otago, 9016
Status
Address
Harbour Cancer & Wellness ( Site 1508)
Auckland, , 0627
Status
Address
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1061)
Bydgoszcz, Kujawsko-pomorskie, 85-796
Status
Address
Pratia MCM Krakow ( Site 1053)
Krakow, Malopolskie, 30-727
Status
Address
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1058)
Siedlce, Mazowieckie, 08-110
Status
Address
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warszawa, Mazowieckie, 02-781
Status
Address
Bialostockie Centrum Onkologii ( Site 1065)
Bialystok, Podlaskie, 15-027
Status
Address
Uniwersyteckie Centrum Kliniczne-Klinika Chirurgii Onkologicznej, Transplantacyjnej i Ogólnej ( Site
Gdańsk, Pomorskie, 80-214
Status
Address
Wojewódzki Szpital Specjalistyczny im. J. Korczaka w Słupsku-Oncologii, Chemioterapii ( Site 1064)
Słupsk, Pomorskie, 76-200
Status
Address
Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 1056)
Gliwice, Slaskie, 44-101
Status
Address
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 1054)
Kielce, Swietokrzyskie, 25-734
Status
Address
Szpital Kliniczny im. H. Swiecickiego nr 2-Oddział Kliniczny Onkologii Klinicznej i Doświadczalnej (
Poznan, Wielkopolskie, 60-780
Status
Address
Zachodniopomorskie Centrum Onkologii ( Site 1063)
Szczecin, Zachodniopomorskie, 71-730
Status
Address
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 1161)
Port Elizabeth, Eastern Cape, 6055
Status
Address
Medical Oncology Centre of Rosebank ( Site 1160)
Johannesburg, Gauteng, 2196
Status
Address
Wilgers Oncology Centre ( Site 1154)
Pretoria, Gauteng, 0040
Status
Address
Curo Oncology ( Site 1158)
Pretoria, Gauteng, 0084
Status
Address
LIFE GROENKLOOF-Mary Potter Cancer Centre ( Site 1152)
Pretoria, Gauteng, 0181
Status
Address
Sandton Oncology Medical Group (Pty) Ltd-Research ( Site 1151)
Sandton, Gauteng, 2196
Status
Address
The Oncology Centre ( Site 1157)
Durban, Kwazulu-Natal, 4091
Status
Address
Abraham Oncology ( Site 1150)
Richards Bay, Kwazulu-Natal, 3900
Status
Address
Cape Town Oncology Trials ( Site 1155)
Cape Town, Western Cape, 7570
Status
Address
Cancercare Rondebosch Oncology-Clinical trials ( Site 1159)
Rondebosch, Western Cape, 7700
Status
Address
Institut Català d'Oncologia - L'Hospitalet ( Site 1202)
L'Hospitalet de Llobregat, Barcelona, 08908
Status
Address
Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1203)
Doniostia - San Sebastian, Gipuzkoa, 20014
Status
Address
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1204)
Madrid, Madrid, Comunidad De, 28034
Status
Address
H.R.U Málaga - Hospital General-Oncology ( Site 1201)
Málaga, Malaga, 29011
Status
Address
Hospital General Universitario de Valencia ( Site 1200)
Valencia, Valenciana, Comunitat, 46014
Status
Address
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 1205)
Sevilla, , 41009
Status
Address
Länssjukhuset Ryhov-Onkologkliniken ( Site 1253)
Jönköping, Jonkopings Lan, 553 05
Status
Address
Karolinska Universitetssjukhuset Solna ( Site 1252)
Stockholm, Stockholms Lan, 171 64
Status
Address
University Hospital Basel ( Site 1303)
Basel, Basel-Stadt, 4056
Status
Address
Inselspital Bern ( Site 1301)
Bern, Berne, 3010
Status
Address
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1307)
Genève, Geneve, 1211
Status
Address
Ospedale Regionale Bellinzona e Valli ( Site 1308)
Bellinzona, Ticino, 6500
Status
Address
CHUV (centre hospitalier universitaire vaudois) ( Site 1304)
Lausanne, Vaud, 1011
Status
Address
Hôpital de Sion ( Site 1305)
Sion, Wallis, 1951
Status
Address
UniversitätsSpital Zürich-Dermatology ( Site 1300)
Zürich Flughafen, Zurich, 8058
Status
Address
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 1306)
Sankt Gallen, , 9007
Status
Address
Ankara City Hospital-Medical Oncology ( Site 1357)
Cankaya, Ankara, 06800
Status
Address
I.E.U. Medical Point Hastanesi-Oncology ( Site 1360)
Izmir, Karsiyaka, Izmir, 009035575
Status
Address
Hacettepe Universite Hastaneleri ( Site 1363)
Ankara, , 06230
Status
Address
Liv Hospital Ankara-Oncology ( Site 1353)
Ankara, , 06680
Status
Address
Akdeniz Universitesi Hastanesi-Medical Oncology ( Site 1355)
Antalya, , 07059
Status
Address
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1358)
Istanbul, , 34722
Status
Address
Mersin Sehir Eğitim ve Araştırma Hastanesi-Oncology ( Site 1361)
Mersin, , 33240
Status
Address
Ondokuz Mayıs Universitesi-Oncology department ( Site 1359)
Samsun, , 55139
Status
Address
Addenbrooke's Hospital ( Site 1400)
Cambridge, Cambridgeshire, CB2 2QQ
Status
Address
University College London Hospital ( Site 1405)
London, England, NW1 2PG
Status
Address
Guy's & St Thomas' NHS Foundation Trust-Oncology & Haematology Clinical Trials ( Site 1401)
London, London, City Of, SE1 9RT
